Shopping Cart
Remove All
Your shopping cart is currently empty
BI-1607
Catalog No. T9901A-1820 Copy Product Info
🥰Excellent
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcγRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC).
BI-1607
Copy Product Info🥰Excellent
Catalog No. T9901A-1820
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcγRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC).
BI-1607
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcγRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC). |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy BI-1607 | purchase BI-1607 | BI-1607 cost | order BI-1607
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.